5 Key Takeaways
-
1
Anti-VEGF therapy has transformed the treatment of neovascular age-related macular degeneration (nAMD), improving vision outcomes significantly.
-
2
Second-generation anti-VEGF agents, including brolucizumab, faricimab, and aflibercept HD, offer extended durability and reduced injection frequency.
-
3
Brolucizumab's smaller size and higher molar concentration enhance retinal penetration and binding capacity compared to first-generation agents.
-
4
Vabysmo, a bispecific antibody, targets both VEGF-A and Ang-2, potentially improving fluid control and clinical outcomes over Eylea.
-
5
Clinical trials have shown that Beovu, Vabysmo, and Eylea HD maintain visual acuity while allowing for longer dosing intervals.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.